SOURCE: Medistem Laboratories

September 11, 2007 08:10 ET

Medistem to Meet With Stem Cell Leaders in Province of Alberta

Mission to Support Increasing Ties With Scientific Community and Expansion of Scientific Collaborations

SCOTTSDALE, AZ--(Marketwire - September 11, 2007) - Medistem Laboratories (OTCBB: MDSM) (FRANKFURT: S2U.F) announced today that Thomas Ichim, Chief of Scientific Development, will participate in a mission organized by the Canadian Consulate and the Government of Alberta for promoting scientific interactions between the Arizona-based stem cell company and leading stem cell and cell therapy researchers in Alberta.

"Canadian scientists have been at the forefront of cellular therapy, first by discovering the hematopoietic stem cell, and second by developing the Edmonton Protocol. Both contributions have not only expanded scientific understanding but have saved the lives of numerous patients with cancer and diabetes respectively," said Thomas Ichim. "We are optimistic these discussions will foster additional collaborative initiatives that will replicate the increasingly strong relationship we have with the Lawson Health Research Institute in Ontario, Canada."

In the 2 day mission, Medistem will meet with scientific leaders from the University of Calgary, University of Alberta, as well as the public Canadian biotech Stem Cell Therapeutics (SSS.V).

"Stem Cell Therapeutics is the first company to induce regeneration of damaged brain tissue through administration of drugs that activate the body's own stem cells," said Ichim. "Given Medistem's interest in the area of neural regeneration we are looking forward to learning more about this novel and unique breakthrough made by our Canadian colleagues, as well as looking at ways we could collaborate."

About Medistem Laboratories, Inc.

Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. While drug discovery and development is its primary focus, Medistem has compiled a body of proprietary technologies it outlicenses to commercial entities in markets where stem cell administration is permissible. Due to its licensee relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information